Saluda Medical Launches Evoke For Chronic Pain Relief in Europe

Neuromodulation industry witnessed a watershed in its development as the famous global medical device company Saluda Medical Announces European Commercial Launch of Evoke SCS. Evoke SCS is the first and only ECAP-Controlled, Closed-Loop SCS system for chronic pain relief in the world.

According to the beneficiaries, the mechanism is quite different from the prior systems, and it is more productive and easy. It measures the spinal cord's response to stimulation (via ECAPs, or evoked compound action potentials) and regulates on every pulse to optimize activation within the patient's therapeutic window.  

Dr. Harold Nijhuis is the first user of the ECAP-Controlled Closed-Loop SCS system. He currently is an Anesthesiologist and Pain Management Consultant at St. Antonius Hospital, Nieuwegein, The Netherlands.  

Dr. Nijhuis is quite positive about the implementation of the Evoke system in his hospital and looking for a bright future with the most impactful innovations to help manage chronic pain. “We are already seeing the positive early results on patients with Evoke,” he claims. 

For the physicians, it is a new window to measure each individual patient's neurophysiological response directly to SCS. It will provide objective data to the productive programming for the treatment. It is a great invention, which is going to help a lot of patients globally, he adds. 

Dr. Nijhuis had substantiated the relevance of Evoke SCS in the European Pain Federation 2019, that held last week. He was explaining the clinical advantage of the ability to measure the spinal cord's response to stimulation. 

While the European Union gave the green signal to Evoke System, In the U.S., Evoke is still under investigation through the first double-blinded, randomized, controlled U.S. pivotal study in SCS. Saluda is seeking Australian TGA approval and U.S. FDA approval of Evoke. 

The latest innovation is not just Saluda Medical’s growth and development in neuromodulation, but it will be a milestone in the field as a whole. The firm’s service always focused on the excellent patient outcomes, says John Parker, CEO of Saluda Medical.